Acute Lymphoblastic Lekumia is the most prevalent cancer type in children. While most data from Turkey primarily focuses on BFM protocols, our study uniquely concentrates on the COG ALL protocols. In this study we aimed to analyze the molecular characteristics and outcomes of the patients diagnosed with ALL who were treated at the Pediatric Hematology and Oncology department of Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine, Altunizade Hospital.

We have reported all the cases that have achieved complete treatment of ALL. Patient risks were assessed by diagnosis, demographics, and clinical settings, followed by protocol selection. Analysis of risk stratification involved immunophenotyping, and genetic characteristics.

46 patient participated in the study. Standard risk, high risk and very high risk was observed in 60.5%, 27.9% and 11.6% patients respectively for B ALL and all T-ALL patients were admitted to the high risk group. 28.3% had negative prognostic genetic mutations. At the end of the induction therapy (At the 29th day), 80.4 % of the patients had MRD level below 0,1%. Mean survival time was 71,6 months. 4,3% of patients had bone marrow relapse, and after second-line treatment, are now relapse free.

This study assesses the pediatric ALL patients treated with COG protocols from Turkey in a single center over a span of 16 years. Follow up processes and therapy responses taking into consideration their demographical characteristics, clinical attributes, genetic profiles, complications and outcomes. COG ALL Protocols in Turkey are being used only by the COG international corresponding members and are as promising as the BFM protocols.